Orange, California 92868

  • Positive Bacterial Infections


This is a multicenter, open-label, single-dose pharmacokinetic (PK) study. Infants, children, and adolescents will receive a single 10 mg/kg dose of telavancin infused intravenously (IV) over 60 minutes


Inclusion Criteria: - Subject is aged >3 months to 17 years (inclusive) and has a weight within the 3rd to 97th percentile (inclusive) for age and sex - Subject requires or recently completed systemic antibiotic therapy for the treatment or prevention of a known or suspected bacterial infection Exclusion Criteria: - Subject has an estimated creatinine clearance <50 mL/min/1.73 m2 (Schwartz equation) - Subject has a history of allergies or hypersensitivities to glycopeptide antibiotics (e.g., vancomycin), telavancin, or the formulation excipients - Subject has clinically relevant cardiac abnormality, in the opinion of the investigator - Subject was treated with an investigational drug within 30 days or five half-lives, whichever is longer, before study entry



Primary Contact:

Study Director
Medical Monitor
Cumberland Pharmaceuticalsc

Cumberland Pharmaceuticals Inc.
Phone: 1-615-255-0068

Backup Contact:


Location Contact:

Orange, California 92868
United States

Antonio C. Arrieta, M.D.

Site Status: Recruiting

Data Source:

Date Processed: September 18, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.